Nubeqa (darolutamide) increases overall survival in men with mCSPC/HSPC when added to androgen-deprivation treatment (ADT) with docetaxel: ARASENS phase III study - DelveInsight Business Research
Darolutamide For Castration-Resistant Prostate Cancer. - Abstract - Europe PMC
ASCO 2020: Overall Survival Results of Phase III ARAMIS Study of Darolutamide Added to Androgen Deprivation Therapy for Non-metastatic Castration-Resistant Prostate Cancer
ASCO GU 2022: ARASENS Trial Overall Survival With Darolutamide Versus Placebo in Combination With ADT and Docetaxel for mHSPC
Active clinical trials to determine optimal sequence or combination... | Download Table
Selected Ongoing Trials With Darolutamide In Prostate Cancer | Download Scientific Diagram
Updates and Insights on the Medical Science of Prostate Cancer (Transcript)
EAU 2019: Conclusions from Recent Oncology Meetings Regarding: Hormone Naïve Prostate Cancer
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer | NEJM
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer | NEJM
ASCO GU 2022: ARASENS Trial Overall Survival With Darolutamide Versus Placebo in Combination With ADT and Docetaxel for mHSPC
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer | NEJM
Darolutamide Extends Survival in Metastatic Prostate Cancer - NCI
Launch of ARANOTE Study Augments Development Program for Darolutamide in Prostate Cancer
ARASENS: Darolutamide Plus ADT and Docetaxel May Become New Standard of Care for mHSPC
Data day: Trial results deliver hope for prostate cancer patients - PharmaTimes
Bayer raises peak sales for Nubeqa to exceed three billion euro amid positive Phase III ARASENS trial data
ASCO GU 2018: TPS383 - ARASENS: A Phase 3 Trial of Darolutamide in Combination with Docetaxel for Men with Metastatic Hormone-sensitive Prostate Cancer
Interpreting Data From the ARASENS Trial in Metastatic HSPC
ESMO 2021: Discussion on the Final Overall Survival Analysis From the ARCHES Study: Enzalutamide + ADT in Men With mHSPC
ARASENS: Darolutamide Plus ADT and Docetaxel May Become New Standard of Care for mHSPC
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting | SpringerLink
Addition of darolutamide to ADT, docetaxel prolongs OS in metastatic prostate cancer
Selecting Optimal Therapy for mHSPC: Design of the ARASENS Trial
